These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37137847)

  • 1. [Different treatment strategies in patients with HBeAg-positive and negative chronic hepatitis B].
    Zhang MY; Chen SY; Sun YM; You H
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):238-241. PubMed ID: 37137847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
    Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.
    Li M; Sun F; Bi X; Lin Y; Yang L; Lu Y; Zhang L; Wan G; Yi W; Zhao L; Xie Y
    Virol Sin; 2022 Jun; 37(3):390-397. PubMed ID: 35257963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients.
    Na JH; Kim JH; Choe WH; Kwon SY; Yoo BC
    Korean J Gastroenterol; 2021 Jun; 77(6):285-293. PubMed ID: 34158448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
    Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
    Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
    [No Abstract]   [Full Text] [Related]  

  • 10. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
    Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
    Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.
    Yang J; Chen J; Ye P; Jin L; Wu W; Sheng G; Li LJ
    J Transl Med; 2014 Jun; 12():183. PubMed ID: 24962263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
    Demirören K; Kocamaz H; Doğan Y
    Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
    J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
    Chuaypen N; Sriprapun M; Praianantathavorn K; Payungporn S; Wisedopas N; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2017 Jan; 89(1):130-138. PubMed ID: 27307409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
    Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
    Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.